Abstract LB350: Discovery and characterization of ABK-EGFR-1, a 4th generation EGFR C797S Inhibitor with excellent selectivity and brain penetration
Year: 2026
Type: conference-abstract
Source: Cancer Research
Institution: Abbisko Therapeutics Co., Ltd. (China)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7154742223
Cites:
Cited by:
Related to: